Guard of Delinquency? A Role of Microglia in Inflammatory Neurodegenerative Diseases of the CNS
- 372 Downloads
Activation of microglia and inflammation-mediated neurotoxicity are believed to play an important role in the pathogenesis of several neurodegenerative disorders, including multiple sclerosis. Studies demonstrate complex functions of activated microglia that can lead to either beneficial or detrimental outcomes, depending on the form and the timing of activation. Combined with genetic and environmental factors, overactivation and dysregulation of microglia cause progressive neurotoxic consequences which involve a vicious cycle of neuron injury and unregulated neuroinflammation. Thus, modulation of microglial activation appears to be a promising new therapeutic target. While current therapies do attempt to block activation of microglia, they indiscriminately inhibit inflammation thus also curbing beneficial effects of inflammation and delaying recovery. Multiple signaling cascades, often cross-talking, are involved in every step of microglial activation. One of the key challenges is to understand the molecular mechanisms controlling cytokine expression and phagocytic activity, as well as cell-specific consequences of dysregulated cytokine expression. Further, a better understanding of how the integration of multiple cytokine signals influences the function or activity of individual microglia remains an important research objective to identify potential therapeutic targets for clinical intervention to promote repair.
KeywordsMicroglia Inflammation Neurodegeneration Activation Signaling Pathway
This work was supported by the China National Natural Science Fund Project No. 812272791.
- 8.Griffin, W. S. (2006). Inflammation and neurodegenerative diseases. American Journal of Clinical Nutrition, 2006(83), 470S–474S.Google Scholar
- 18.Ngoi, S. M., Sylvester, F. A., & Vella, A. T. (2011). The role of microbial byproducts in protection against immunological disorders and the hygiene hypothesis. Discovery Medicines, 12, 405–412.Google Scholar
- 19.Schulte, C., & Gasser, T. (2011). Genetic basis of Parkinson’s disease: Inheritance, penetrance, and expression. Application of Clinical Genetics, 4, 80.Google Scholar
- 33.Lehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., et al. (2003). Activation of innate immunity in the CNS triggers neurodegeneration through a toll-like receptor 4-dependent pathway. Proceedings of the National Academy of Sciences of the United States of America, 100, 8514–8519.PubMedCentralPubMedCrossRefGoogle Scholar
- 38.Lin, M. W., Tsao, L. T., Chang, L. C., Chen, Y. L., Huang, L. J., Kuo, S. C., et al. (2007). Inhibition of lipopolysaccharide-stimulated NO production by a novel synthetic compound CYL-4d in RAW 264.7 macrophages involving the blockade of MEK4/JNK/AP-1 pathway. Biochemical Pharmacology, 73, 1796–1806.PubMedCrossRefGoogle Scholar
- 42.Cassatella, M. A., Gasperini, S., Bovolenta, C., Calzetti, F., Vollebregt, M., Scapini, P., et al. (1999). Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: Evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood, 94, 2880–2889.PubMedGoogle Scholar
- 45.Wong, P. K., Egan, P. J., Croker, B. A., O’Donnell, K., Sims, N. A., Drake, S., et al. (2006). SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. Journal of Clinical Investigation, 116, 1571–1581.PubMedCentralPubMedCrossRefGoogle Scholar